UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 28, 2014
OR
TRANSITION REPORT PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _______ to _______
COMMISSION FILE NUMBER 1-3619
----
PFIZER INC.
(Exact name of registrant as specified in its charter)
DELAWARE
(State of Incorporation)
13-5315170
(I.R.S. Employer Identification No.)
235 East 42nd Street, New York, New York 10017
(Address of principal executive offices) (zip code)
(212) 733-2323
(Registrant s telephone number)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.
YES X
NO ___
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
YES X
NO ___
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act (check one):
Large Accelerated filer X Accelerated filer ___ Non-accelerated filer ___ Smaller reporting company ___
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
YES ____
NO X
At November 3, 2014, 6,300,657,237 shares of the issuer s voting common stock were outstanding.
Table of Contents
PART I. FINANCIAL INFORMATION
Page
Item 1.
Financial Statements
Condensed Consolidated Statements of Income for the three and nine months ended September 28, 2014 and September 29, 2013
Condensed Consolidated Statements of Comprehensive Income for the three and nine months ended September 28, 2014 and September 29, 2013
Condensed Consolidated Balance Sheets as of September 28, 2014 and December 31, 2013
Condensed Consolidated Statements of Cash Flows for the nine months ended September 28, 2014 and September 29, 2013
Notes to Condensed Consolidated Financial Statements
Review Report of Independent Registered Public Accounting Firm
43
Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
44
Item 3.
Quantitative and Qualitative Disclosures About Market Risk
95
Item 4.
Controls and Procedures
95
PART II. OTHER INFORMATION
Item 1.
Legal Proceedings
96
Item 1A.
Risk Factors
96
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds
97
Item 3.
Defaults Upon Senior Securities
97
Item 4.
Mine Safety Disclosures
97
Item 5.
Other Information
97
Item 6.
Exhibits
98
Signature
99
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(UNAUDITED)
Three Months Ended
Nine Months Ended
(MILLIONS, EXCEPT PER COMMON SHARE DATA)
September 28,
2014
September 29,
2013
September 28,
2014
September 29,
2013
Revenues
12,361
12,643
36,487
38,026
Costs and expenses:
Cost of sales(a)
2,368
2,287
6,875
6,792
Selling, informational and administrative expenses(a)
3,556
3,395
10,116
10,203
Research and development expenses(a)
1,802
1,627
5,184
4,867
Amortization of intangible assets
972
1,117
3,090
3,476
Restructuring charges and certain acquisition-related costs
(19
233
120
547
Other (income)/deductions net
94
411
665
(514
Income from continuing operations before provision for taxes on income
3,587
3,573
10,437
12,655
Provision for taxes on income
911
985
2,575
3,876
Income from continuing operations
2,676
2,588
7,862
8,779
Discontinued operations:
Income from discontinued operations net of tax
(3
36
326
Gain on disposal of discontinued operations net of tax
(25
70
10,393
Discontinued operations net of tax
(3
11
70
10,719
Net income before allocation to noncontrolling interests
2,672
2,599
7,932
19,498
Less: Net income attributable to noncontrolling interests
25
63
Net income attributable to Pfizer Inc.
2,666
2,590
7,907
19,435
Earnings per common share basic:
Income from continuing operations attributable to Pfizer Inc. common shareholders
0.42
0.39
1.23
1.26
Discontinued operations net of tax
0.01
1.54
Net income attributable to Pfizer Inc. common shareholders
0.42
0.39
1.24
2.80
Earnings per common share diluted:
Income from continuing operations attributable to Pfizer Inc. common shareholders
0.42
0.39
1.22
1.25
Discontinued operations net of tax
0.01
1.52
Net income attributable to Pfizer Inc. common shareholders
0.42
0.39
1.23
2.77
Weighted-average shares basic
6,330
6,581
6,363
6,938
Weighted-average shares diluted
6,403
6,656
6,441
7,016
Cash dividends paid per common share
0.26
0.24
0.78
0.72
(a)
Excludes amortization of intangible assets, except as disclosed in Note 9B. Goodwill and Other Intangible Assets: Other Intangible Assets.
Amounts may not add due to rounding.
See Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(UNAUDITED)
Three Months Ended
Nine Months Ended
(MILLIONS OF DOLLARS)
September 28,
2014
September 29,
2013
September 28,
2014
September 29,
2013
Net income before allocation to noncontrolling interests
2,672
2,599
7,932
19,498
Foreign currency translation adjustments
(431
(21
(273
(1,068
Reclassification adjustments(a)
(62
171
(430
(21
(334
(897
Unrealized holding gains/(losses) on derivative financial instruments
(172
10
(229
143
Reclassification adjustments for realized (gains)/losses(b)
441
(339
527
(37
269
(329
298
106
Unrealized holding gains/(losses) on available-for-sale securities
(200
325
(107
137
Reclassification adjustments for realized (gains)/losses(b)
15
10
(163
(74
(185
335
(270
63
Benefit plans: actuarial gains/(losses), net
18
(13
13
34
Reclassification adjustments related to amortization(c)
48
137
146
438
Reclassification adjustments related to settlements, net(c)
19
54
58
147
Other
42
(28
16
112
127
150
233
731
Benefit plans: prior service credits and other
Reclassification adjustments related to amortization(c)
(19
(16
(55
(45
Reclassification adjustments related to curtailments, net(c)
12
(9
Other
(1
(4
(18
(14
(44
(55
Other comprehensive income/(loss), before tax
(238
121
(118
(52
Tax provision on other comprehensive income/(loss)(d)
83
80
71
443
Other comprehensive income/(loss) before allocation to noncontrolling interests
(320
41
(189
(495
Comprehensive income before allocation to noncontrolling interests
2,352
2,640
7,743
19,003
Less: Comprehensive income/(loss) attributable to noncontrolling interests
(32
32
(2
Comprehensive income attributable to Pfizer Inc.
2,351
2,672
7,711
19,005
(a)
Reclassified into Gain on disposal of discontinued operations net of tax in the condensed consolidated statements of income.
(b)
Reclassified into Other (income)/deductions net in the condensed consolidated statements of income.
(c)
Generally reclassified, as part of net periodic pension cost, into Cost of sales, Selling, informational and administrative expenses, and/or Research and development expenses, as appropriate, in the condensed consolidated statements of income. For additional information, see Note 10. Pension and Postretirement Benefit Plans.
(d)
See Note 5C. Tax Matters: Tax Provision on Other Comprehensive Income/(Loss).
Amounts may not add due to rounding.
See Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(MILLIONS OF DOLLARS)
September 28,
2014
December 31,
2013
(Unaudited)
Assets
Cash and cash equivalents
2,437
2,183
Short-term investments
31,009
30,225
Accounts receivable, less allowance for doubtful accounts: 2014 $388; 2013 $478
9,955
9,357
Inventories
6,355
6,166
Current deferred tax assets and other current tax assets
4,687
4,624
Other current assets
2,545
3,689
Total current assets
56,987
56,244
Long-term investments
18,451
16,406
Property, plant and equipment, less accumulated depreciation
12,032
12,397
Goodwill
42,724
42,519
Identifiable intangible assets, less accumulated amortization
36,374
39,385
Noncurrent deferred tax assets and other noncurrent tax assets
1,373
1,554
Other noncurrent assets
3,421
3,596
Total assets
171,362
172,101
Liabilities and Equity
Short-term borrowings, including current portion of long-term debt
5,389
6,027
Accounts payable
2,973
3,234
Dividends payable
1,663
Income taxes payable
892
678
Accrued compensation and related items
1,841
1,792
Other current liabilities
8,824
9,972
Total current liabilities
19,920
23,366
Long-term debt
31,666
30,462
Pension benefit obligations, net
4,364
4,635
Postretirement benefit obligations, net
2,591
2,668
Noncurrent deferred tax liabilities
26,320
25,590
Other taxes payable
3,930
3,993
Other noncurrent liabilities
4,266
4,767
Total liabilities
93,057
95,481
Commitments and Contingencies
Preferred stock
30
33
Common stock
455
453
Additional paid-in capital
78,498
77,283
Treasury stock
(71,820
(67,923
Retained earnings
74,292
69,732
Accumulated other comprehensive loss
(3,467
(3,271
Total Pfizer Inc. shareholders equity
77,988
76,307
Equity attributable to noncontrolling interests
317
313
Total equity
78,305
76,620
Total liabilities and equity
171,362
172,101
Amounts may not add due to rounding.
See Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
Nine Months Ended
(MILLIONS OF DOLLARS)
September 28,
2014
September 29,
2013
Operating Activities
Net income before allocation to noncontrolling interests
7,932
19,498
Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:
Depreciation and amortization
4,206
4,921
Asset write-offs and impairments
414
908
Gain associated with the transfer of certain product rights to an equity-method investment
(459
Gain on disposal of discontinued operations
(65
(10,501
Deferred taxes from continuing operations
766
1,667
Deferred taxes from discontinued operations
(23
Share-based compensation expense
424
418
Benefit plan contributions (in excess of)/less than expense
(208
242
Other adjustments, net
(464
38
Other changes in assets and liabilities, net of acquisitions and divestitures
(1,519
(4,749
Net cash provided by operating activities
11,485
11,960
Investing Activities
Purchases of property, plant and equipment
(845
(789
Purchases of short-term investments
(36,294
(33,927
Proceeds from redemptions and sales of short-term investments
32,883
29,008
Net (purchases of)/proceeds from redemptions/sales of investments with original maturities of 90 days or less
4,945
(2,177
Purchases of long-term investments
(9,254
(8,746
Proceeds from redemptions and sales of long-term investments
4,637
5,943
Acquisitions of businesses, net of cash acquired
(195
(15
Acquisitions of intangible assets
(342
(177
Other investing activities, net
325
194
Net cash used in investing activities
(4,140
(10,686
Financing Activities
Proceeds from short-term borrowings
3,723
Principal payments on short-term borrowings
(3
(3,776
Net proceeds from/(payments on) short-term borrowings with original maturities of 90 days or less
(2,758
1,831
Proceeds from issuance of long-term debt(a)
4,491
6,618
Principal payments on long-term debt
(786
(2,396
Purchases of common stock
(3,801
(11,643
Cash dividends paid
(4,970
(5,026
Proceeds from exercise of stock options
704
1,370
Other financing activities, net
56
68
Net cash used in financing activities
(7,060
(9,231
Effect of exchange-rate changes on cash and cash equivalents
(30
(72
Net increase/(decrease) in cash and cash equivalents
255
(8,029
Cash and cash equivalents, beginning
2,183
10,081
Cash and cash equivalents, end
2,437
2,052
Supplemental Cash Flow Information
Non-cash transactions:
Sale of subsidiary common stock (Zoetis) for Pfizer common stock(b)
11,408
Exchange of subsidiary common stock (Zoetis) for the retirement of Pfizer commercial paper issued in 2013(b)
2,479
Exchange of subsidiary senior notes (Zoetis) for the retirement of Pfizer commercial paper issued in 2012(b)
992
Transfer of certain product rights to an equity-method investment (Hisun Pfizer)(c)
1,233
Cash paid during the period for:
Income taxes
1,484
1,799
Interest
1,329
1,512
(a)
In 2013, includes $2.6 billion from the issuance of senior notes by Zoetis (our former Animal Health subsidiary), net of the $1.0 billion non-cash exchange of Zoetis senior notes for the retirement of Pfizer commercial paper issued in 2012. See Note 2B. Acquisition, Divestiture, Licensing Arrangements and Equity-Method Investments: Divestiture.
(b)
See Note 2B. Acquisition, Divestiture, Licensing Arrangements and Equity-Method Investments: Divestiture.
(c)
See Note 2D. Acquisition, Divestiture, Licensing Arrangements and Equity-Method Investments: Equity-Method Investments.
Amounts may not add due to rounding.
See Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Note 1. Basis of Presentation and Significant Accounting Policies
A. Basis of Presentation
We prepared the condensed consolidated financial statements following the requirements of the U.S. Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by accounting principles generally accepted in the United States of America (U.S. GAAP) can be condensed or omitted.
Balance sheet amounts and operating results for subsidiaries operating outside the U.S. are as of and for the three and nine months ended August 24, 2014 and August 25, 2013.
In the condensed consolidated statements of comprehensive income, we have revised the presentation of other comprehensive income/(loss) shown in prior periods for derivative financial instruments and available-for-sale securities, as certain items had been reported net. In the condensed consolidated statements of cash flows, we have revised the classification of certain items shown in prior periods, none of which had a significant impact.
On June 24, 2013, we completed the full disposition of our Animal Health business, Zoetis Inc. (Zoetis), and recognized a gain of approximately $10.4 billion, net of tax, in Gain on disposal of discontinued operations net of tax in the condensed consolidated statements of income for the nine months ended September 29, 2013. The operating results of this business through June 24, 2013, the date of disposal, are reported as Discontinued operations net of tax in the condensed consolidated statements of income for the nine months ended September 29, 2013. For additional information, see Note 2B. Acquisition, Divestiture, Licensing Arrangements and Equity-Method Investments: Divestiture.
Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.
We are responsible for the unaudited financial statements included in this Quarterly Report on Form 10-Q. The financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of our condensed consolidated balance sheets and condensed consolidated statements of income.
The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2013 Annual Report on Form 10-K.
Certain amounts in the condensed consolidated financial statements and associated notes may not add due to rounding. All percentages have been calculated using unrounded amounts.
B. Adoption of New Accounting Standards
We adopted the following new accounting and disclosure standards as of January 1, 2014 and there were no impacts to our condensed consolidated financial statements:
A new standard that clarified the accounting for cumulative translation adjustment (CTA) upon derecognition of a group of assets that is a business or an equity-method investment within a foreign entity.
A new standard regarding the measurement of obligations resulting from joint and several liability arrangements that may include debt agreements, other contractual obligations and settled litigation or judicial rulings.
C. Fair Value
Our fair value methodologies depend on the following types of inputs:
Quoted prices for identical assets or liabilities in active markets (Level 1 inputs).
Quoted prices for similar assets or liabilities in active markets or quoted prices for identical or similar assets or liabilities in markets that are not active or are directly or indirectly observable (Level 2 inputs).
Unobservable inputs that reflect estimates and assumptions (Level 3 inputs).
A single estimate of fair value can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Note 2. Acquisition, Divestiture, Licensing Arrangements and Equity-Method Investments
A. Acquisition
InnoPharma, Inc. (InnoPharma)
On September 24, 2014, we completed our acquisition of InnoPharma, a privately-held pharmaceutical development company, for an upfront cash payment of $225 million and contingent consideration with an estimated acquisition-date fair value of approximately $67 million. The contingent consideration consists of up to $135 million in additional milestone payments based on application filing with and acceptance by the U.S. Food and Drug Administration (FDA), or approval of marketing applications related to certain pipeline products by the FDA. We believe this acquisition represents a potential innovative growth opportunity for our sterile injectables portfolio in areas such as oncology and central nervous disorders. In connection with this acquisition, we recorded $247 million in Identifiable intangible assets, consisting of $212 million in In-process research and development (IPR&D) and $35 million in Developed technology rights; $81 million in net deferred tax liabilities; and $125 million in Goodwill. The allocation of the consideration transferred to the assets acquired and the liabilities assumed has not been finalized.
B. Divestiture
Animal Health Business (Zoetis)
On June 24, 2013, we completed the full disposition of Zoetis. The full disposition was completed through a series of steps, including, in the first quarter of 2013, the formation of Zoetis and an initial public offering (IPO) of an approximate 19.8% interest in Zoetis and, in the second quarter of 2013, an exchange offer for the remaining 80.2% interest.
With respect to the formation and disposition of Zoetis, in the first nine months of 2013:
Formation of Zoetis On January 28, 2013, our then wholly owned subsidiary, Zoetis, issued $3.65 billion aggregate principal amount of senior notes. Also, on January 28, 2013, we transferred to Zoetis substantially all of the assets and liabilities of our Animal Health business in exchange for all of the Class A and Class B common stock of Zoetis, $1.0 billion of the $3.65 billion of Zoetis senior notes, and an amount of cash equal to substantially all of the cash proceeds received by Zoetis from the remaining $2.65 billion of senior notes issued. The $1.0 billion of Zoetis senior notes received by Pfizer were exchanged by Pfizer for the retirement of Pfizer commercial paper issued in 2012, and the cash proceeds received by Pfizer of approximately $2.6 billion were used for dividends and stock buybacks.
Initial Public Offering (19.8% Interest) On February 6, 2013, an IPO of the Class A common stock of Zoetis was completed, pursuant to which we sold 99.015 million shares of Class A common stock of Zoetis (all of the Class A common stock, including shares sold pursuant to the underwriters' option to purchase additional shares, which was exercised in full) in exchange for the retirement of approximately $2.5 billion of Pfizer commercial paper issued in 2013. The Class A common stock sold in the IPO represented approximately 19.8% of the total outstanding Zoetis shares. The excess of the consideration received over the net book value of our divested interest was approximately $2.3 billion and was recorded in Additional paid-in capital.
Exchange Offer (80.2% Interest) On June 24, 2013, we exchanged all of our remaining interest in Zoetis for Pfizer common stock and recognized a gain on sale of approximately $10.4 billion net of income taxes resulting from certain legal entity reorganizations, which was recorded in Gain on disposal of discontinued operations net of tax in the condensed consolidated statements of income for the nine months ended September 29, 2013.
The operating results of the Animal Health business through June 24, 2013, the date of disposal, are reported as Income from discontinued operations net of tax in the condensed consolidated statements of income for the nine months ended September 29, 2013.
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Total Discontinued Operations
The following table provides the components of Discontinued operations net of tax, virtually all of which relates to Zoetis:
Three Months Ended
Nine Months Ended
(MILLIONS OF DOLLARS)
September 28,
2014
September 29,
2013
September 28,
2014
September 29,
2013
Revenues
2,201
Pre-tax income from discontinued operations(b)
(2
32
421
Provision for taxes on income(a)
(4
95
Income from discontinued operations net of tax
(3
36
326
Pre-tax gain on disposal of discontinued operations(b)
(38
65
10,501
Provision for taxes on income(b), (c)
(13
(4
108
Gain on disposal of discontinued operations net of tax(b)
(25
70
10,393
Discontinued operations net of tax
(3
11
70
10,719
(a)
Includes a deferred tax expense of $2 million and a deferred tax benefit of $4 million for the three months ended September 28, 2014 and September 29, 2013, respectively, and a deferred tax benefit of $23 million for the nine months ended September 29, 2013. Deferred taxes for the first nine months of 2014 were nil.
(b)
For the three months and nine months ended September 28, 2014 and for the three months ended September 29, 2013, represents post-close adjustments.
(c)
For the nine months ended September 29, 2013, reflects income taxes resulting from certain legal entity reorganizations.
The net cash flows of our discontinued operations for each of the categories of operating, investing and financing activities are not significant for the nine months ended September 29, 2013, except that financing activities include the cash proceeds from the issuance of senior notes by Zoetis.
C. Licensing Arrangements
Cellectis SA (Cellectis)
On June 18, 2014, we entered into a global strategic arrangement with Cellectis to develop Chimeric Antigen Receptor T-cell (CAR-T) immunotherapies in the field of oncology directed at select cellular surface antigen targets. In August 2014, we made an upfront payment of $80 million to Cellectis, which was recorded in Research and development expenses, and we will also fund research and development costs associated with the 15 Pfizer-selected targets and the four Cellectis-selected targets within the arrangement. Cellectis is eligible to receive development, regulatory and commercial milestone payments of up to $185 million per product that resulted from the Pfizer-selected targets. Cellectis is also eligible to receive tiered royalties on net sales of any products that are commercialized by Pfizer. In addition, in August 2014, we acquired approximately 10% of the Cellectis capital through the purchase of newly issued shares, for a total investment of approximately $35 million.
Nexium Over-the-Counter Rights
In connection with our August 2012 agreement with AstraZeneca PLC (AstraZeneca) for the exclusive, global, over-the-counter rights for Nexium, a leading prescription drug currently approved to treat the symptoms of gastroesophageal reflux disease, (i) on May 27, 2014, we launched Nexium 24HR in the U.S., and on July 11, 2014, we paid AstraZeneca a related $200 million product launch milestone payment and (ii) on August 1, 2014, we launched Nexium Control in Europe, and on September 15, 2014, we paid AstraZeneca a related $50 million product launch milestone payment. The milestone payments for this Consumer Healthcare asset acquisition have been recorded in Identifiable intangible assets, less accumulated amortization in the condensed consolidated balance sheet and will be amortized over their estimated useful lives. AstraZeneca is eligible to receive future milestone payments of up to $300 million, based on product launches outside the U.S. and level of worldwide sales and is eligible to receive royalty payments, based on worldwide sales.
D. Equity-Method Investments
Investment in Laborat rio Teuto Brasileiro (Teuto)
We have an option to acquire the remaining 60% of Teuto, a 40%-owned generics company in Brazil, beginning in 2014, and Teuto s majority shareholders have an option to sell their 60% stake to us beginning in 2015.
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
In the third quarter and first nine months of 2013, we recorded an estimated loss of approximately $223 million related to the net call/put option and an impairment loss of $32 million related to our equity-method investment, both of which were recorded in Other (income)/deductions net.
In the third quarter and first nine months of 2014, we recorded income of approximately $90 million resulting from a decline in the estimated loss from the aforementioned option, which was recorded in Other (income)/deductions net.
Investment in ViiV Healthcare Limited (ViiV)
Our minority ownership interest in ViiV, a company formed by Pfizer and GlaxoSmithKline plc (GSK) to focus solely on research, development and commercialization of human immunodeficiency virus (HIV) medicines, was impacted by the following events:
The January 21, 2014 European Commission approval of Tivicay (dolutegravir), a product for the treatment of HIV-1 infection, developed by ViiV. This approval triggered a reduction in our equity interest in ViiV from 12.6% to 11.7%, effective April 1, 2014. As a result, in the first nine months of 2014, we recognized a loss of approximately $30 million in Other (income)/deductions net; and
The August 12, 2013 FDA approval of Tivicay (dolutegravir). This approval triggered a reduction in our interest in ViiV from 13.5% to 12.6%, effective October 1, 2013. As a result, in the third quarter and first nine months of 2013, we recognized a loss of approximately $31 million in Other (income)/deductions net.
Investment in Hisun Pfizer Pharmaceuticals Company Limited (Hisun Pfizer)
In connection with the September 6, 2012 formation of Hisun Pfizer in conjunction with Zhejiang Hisun Pharmaceuticals Co., Ltd. (Hisun), a leading pharmaceutical company in China, in the first quarter of 2013, we and Hisun contributed certain assets to Hisun Pfizer. Hisun Pfizer is 49% owned by Pfizer and 51% owned by Hisun. Our contributions constituted a business, as defined by U.S. GAAP, and in the first nine months of 2013, we recognized a pre-tax gain of approximately $459 million in Other (income) deductions net, reflecting the transfer of the business to Hisun Pfizer (including an allocation of goodwill from our former Emerging Markets reporting unit as part of the carrying amount of the business transferred). Since we hold a 49% interest in Hisun Pfizer, we had an indirect retained interest in the contributed assets. As such, 49% of the gain, or $225 million, represented the portion of the gain associated with that indirect retained interest.
Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives
We incur significant costs in connection with acquiring, integrating and restructuring businesses and in connection with our global cost-reduction/productivity initiatives. For example:
In connection with acquisition activity, we typically incur costs associated with executing the transactions, integrating the acquired operations (which may include expenditures for consulting and the integration of systems and processes), and restructuring the combined company (which may include charges related to employees, assets and activities that will not continue in the combined company); and
In connection with our cost-reduction/productivity initiatives, we typically incur costs and charges associated with site closings and other facility rationalization and optimization actions, workforce reductions and the expansion of shared services, including the development of global systems.
All of our businesses and functions may be impacted by these actions, including sales and marketing, manufacturing and research and development (R&D), as well as groups such as information technology, shared services and corporate operations.
At the end of 2013, we had substantially completed many of the initiatives launched in prior periods. In early 2014, we announced that we would be incurring costs in 2014-2016 related to new programs: our new global commercial structure reorganization and additional cost-reduction/productivity initiatives.
In 2014, we have the following initiatives underway:
Manufacturing plant network rationalization and optimization, where execution timelines are necessarily long. Our plant network strategy is expected to result in the exit of eight sites over the next several years (down from 10 sites, previously, as two sites have been sold). In connection with these activities, during 2014-2016, we expect to incur costs of approximately $400 million associated with prior acquisition activity and costs of approximately $1.4 billion associated with new non-acquisition-related cost-reduction initiatives.
10
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
New global commercial structure reorganization, which primarily includes the streamlining of certain functions, the realignment of regional locations and colleagues to support the businesses, as well as implementing the necessary system changes to support future reporting requirements. In connection with this reorganization, during 2014-2016, we expect to incur costs of approximately $350 million.
Other new cost-reduction/productivity initiatives, primarily related to commercial property rationalization and consolidation. In connection with these cost-reduction activities, during 2014-2016, we expect to incur costs of approximately $850 million.
The costs expected to be incurred during 2014-2016, of approximately $3.0 billion in total, include restructuring charges, integration costs, implementation costs and additional depreciation asset restructuring. Of this amount, we expect that about a quarter of the charges will be non-cash.
Current-Period Key Activities
In the first nine months of 2014, we incurred approximately $531 million in cost-reduction and acquisition-related costs (excluding transaction costs) in connection with the aforementioned programs, primarily associated with our manufacturing and sales operations.
The following table provides the components of costs associated with acquisitions and cost-reduction/productivity initiatives:
Three Months Ended
Nine Months Ended
(MILLIONS OF DOLLARS)
September 28,
2014
September 29,
2013
September 28,
2014
September 29,
2013
Restructuring charges(a):
Employee terminations
(51
174
(4
289
Asset impairments
28
115
Exit costs
21
44
36
Total restructuring charges
(38
195
68
440
Integration costs(b)
19
38
53
107
Restructuring charges and certain acquisition-related costs
(19
233
120
547
Additional depreciation asset restructuring recorded in our condensed consolidated statements of income as follows(c):